Participants
’, substance abuse, intellectual disability, psychiatric, psychotic symptoms, schizophrenia, DSM-5
DISEASES, SYSTEMIC DISEASE, DISORDERS, PHYSICAL ILLNESS, DISORDERS
This study was a multicenter, 8-week, open-label, randomized clinical trial conducted at 19 psychiatric centers throughout China and was registered on Clinicaltrials.gov (NCT03451734). The full trial protocol, including sample size calculation, has been published previously [Participants met the following criteria: (1) aged 18–65 years and meeting the criteria for schizophrenia (diagnosed by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or International Classification of Diseases, Tenth Edition (ICD-10)); (2) experiencing a current episode of psychotic symptoms with a duration of illness less than 5 years; (3) with at least one guardian that accompanies the patient and supervises patients’ medications; and (4) who signed an informed consent form. The exclusion criteria for participants were as follows: (1) with serious physical illness; (2) with disorders such as alcohol or substance abuse, intellectual disability, or other specific systemic diseases; (3) who are pregnant or breastfeeding; and (4) enrolled in other clinical trials.